Alnylam Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Reata Pharmaceuticals, Celyad, Sorrento Therapeutics and Moderna.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | |
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | ||
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 17 | Employees 31019% decrease | Employees 5,60044% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 6.6 b | Valuation ($) 11.8 m | Valuation ($) 1.5 m | Valuation ($) 21.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $6.8b (FY, 2023) |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods $4.7b (FY, 2023) |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit $2.2b (FY, 2023) |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income ($4.7b) (FY, 2023) |
Operating ⚠ | |||||
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued 270 (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.8b |
For sources of this data, please see the company profile
View Company Profiles
Reata Pharmaceuticals
HQ
Plano, US
Employees
321↓ 7% decrease
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyModerna
HQ
Cambridge, US
Employees
5,600↑ 44% increase
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View company